Literature DB >> 2964362

Properties of [3H]1-desamino-8-D-arginine vasopressin as a radioligand for vasopressin V2-receptors in rat kidney.

A J Marchingo1, J M Abrahams, E A Woodcock, A I Smith, F A Mendelsohn, C I Johnston.   

Abstract

[3H]1-Desamino-8-D-arginine vasopressin [3H] DDAVP was assessed as a radioligand for vasopressin V2-receptors by studying its membrane-binding characteristics and in vitro autoradiographic localization in rat kidney, a rich source of V2-receptors. [3H]DDAVP bound specifically to a single class of high affinity, low capacity sites in rat medullopapillary membranes. Specific [3H]DDAVP binding at 25 C reached equilibrium after 2 h of incubation and was saturable and linear with protein concentration up to 2.2 mg/ml protein. Saturation analysis gave an equilibrium dissociation constant (Kd) of 0.76 nM. Displacement of [3H]DDAVP binding by unlabeled arginine vasopressin (AVP) and related analogs gave the following order of potency, consistent with that expected for a V2-receptor: DDAVP approximately equal to AVP approximately equal to 1-desamino-AVP greater than lysine vasopressin greater than oxytocin greater than [1-(beta-mercapto-beta, beta-cyclopentamethylene-propionic acid, 2-(O-methyl)tyrosine]AVP. The C-terminal metabolites of AVP, (pGlu4Cyt6)AVP-(4-9), and (pGlu4Cyt6)AVP-(4-8) did not displace [3H]DDAVP binding. No degradation of [3H] DDAVP during incubation could be detected by HPLC analysis. In vitro autoradiography of [3H]DDAVP binding to rat kidney sections showed a very dense localization of displaceable binding over inner and outer medulla, with a much lower density in cortex, consistent with the known major localization of V2-receptors on renal collecting tubules. These studies suggest that [3H]DDAVP is a suitable radioligand for labeling V2-receptors and may be useful in the characterization of vasopressin receptor subtypes in a variety of tissues and in purification of the V2-receptor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2964362     DOI: 10.1210/endo-122-4-1328

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

Review 1.  Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family.

Authors:  J Peter; H Burbach; R A Adan; S J Lolait; F W van Leeuwen; E Mezey; M Palkovits; C Barberis
Journal:  Cell Mol Neurobiol       Date:  1995-10       Impact factor: 5.046

2.  Generation and phenotype of mice harboring a nonsense mutation in the V2 vasopressin receptor gene.

Authors:  J Yun; T Schöneberg; J Liu; A Schulz; C A Ecelbarger; D Promeneur; S Nielsen; H Sheng; A Grinberg; C Deng; J Wess
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

3.  Visualizing microtubule-dependent vasopressin type 2 receptor trafficking using a new high-affinity fluorescent vasopressin ligand.

Authors:  Sylvia Chen; Matthew J Webber; Jean-Pierre Vilardaga; Ashok Khatri; Dennis Brown; Dennis A Ausiello; Herbert Y Lin; Richard Bouley
Journal:  Endocrinology       Date:  2011-08-09       Impact factor: 4.736

4.  Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade.

Authors:  Sophie C Lütken; Soo Wan Kim; Thomas Jonassen; David Marples; Mark A Knepper; Tae-Hwan Kwon; Jørgen Frøkiaer; Søren Nielsen
Journal:  Am J Physiol Renal Physiol       Date:  2009-09-23

Review 5.  Overview of the detection methods for equilibrium dissociation constant KD of drug-receptor interaction.

Authors:  Weina Ma; Liu Yang; Langchong He
Journal:  J Pharm Anal       Date:  2018-05-05

6.  Hyponatremia and V2 vasopressin receptor upregulation: a result of HSP90 inhibition.

Authors:  Qiong Yang; Florian Puhm; Michael Freissmuth; Christian Nanoff
Journal:  Cancer Chemother Pharmacol       Date:  2017-08-04       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.